Boryung BioPharma said Friday that it has launched G-Scanning plus, a test that can diagnose 1,000 neonatal developmental diseases through genetic analysis.
The G-Scanning plus is a test that identifies “DNA duplication mutation disease.” A DNA duplication mutation disease is a combination of a chromosomal microdeletion/micro-redundancy ailment, which occurs due to damage to the integrity of genetic information affected by time loss or addition of specific parts of the chromosome, and chromosomal aneuploidy disease.
The exam confirms genetic information using chromosomal microarray, which can verify the chromosomal integrity, and next-generation sequencing. The system then uses the information to diagnose 1,000 different neonatal developmental diseases through an algorithm developed by the two companies.
“G-Scanning Plus is an effective test that can check 1,000 different kinds of neonatal developmental diseases with a reasonable examination cost,” said Kim Ji-hoon, product manager for G-Scanning Plus. “The test uses microfluidics automated equipment that can provide quick and accurate results with very high accuracy as it uses our genome-wide data integration analysis algorithm."
<© Korea Biomedical Review, All rights reserved.>